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A B S T R A C T
This study aims to map the acute eﬀects of caﬀeine ingestion on grey matter oxygen metabolism and
haemodynamics with a novel MRI method. Sixteen healthy caﬀeine consumers (8 males, age=24.7 ± 5.1) were
recruited to this randomised, double-blind, placebo-controlled study. Each participant was scanned on two days
before and after the delivery of an oral caﬀeine (250 mg) or placebo capsule.
Our measurements were obtained with a newly proposed estimation approach applied to data from a dual
calibration fMRI experiment that uses hypercapnia and hyperoxia to modulate brain blood ﬂow and
oxygenation. Estimates were based on a forward model that describes analytically the contributions of cerebral
blood ﬂow (CBF) and of the measured end-tidal partial pressures of CO2 and O2 to the acquired dual-echo GRE
signal. The method allows the estimation of grey matter maps of: oxygen extraction fraction (OEF), CBF, CBF-
related cerebrovascular reactivity (CVR) and cerebral metabolic rate of oxygen consumption (CMRO2). Other
estimates from a multi inversion time ASL acquisition (mTI-ASL), salivary samples of the caﬀeine concentration
and behavioural measurements are also reported.
We observed signiﬁcant diﬀerences between caﬀeine and placebo on average across grey matter, with OEF
showing an increase of 15.6% (SEM± 4.9%, p < 0.05) with caﬀeine, while CBF and CMRO2 showed diﬀerences
of −30.4% (SEM± 1.6%, p < 0.01) and −18.6% (SEM± 2.9%, p < 0.01) respectively with caﬀeine administration.
The reduction in oxygen metabolism found is somehow unexpected, but consistent with a hypothesis of
decreased energetic demand, supported by previous electrophysiological studies reporting reductions in spectral
power with EEG.
Moreover the maps of the physiological parameters estimated illustrate the spatial distribution of changes
across grey matter enabling us to localise the eﬀects of caﬀeine with voxel-wise resolution. CBF changes were
widespread as reported by previous ﬁndings, while changes in OEF were found to be more restricted, leading to
unprecedented mapping of signiﬁcant CMRO2 reductions mainly in frontal gyrus, parietal and occipital lobes.
In conclusion, we propose the estimation framework based on our novel forward model with a dual
calibrated fMRI experiment as a viable MRI method to map the eﬀects of drugs on brain oxygen metabolism and
haemodynamics with voxel-wise resolution.
Introduction
Functional MRI (fMRI) has been widely applied in research and
clinical settings to infer brain activity. However, changes in blood
oxygenation level dependent (BOLD) signal do not quantify local brain
activity (Ekstrom, 2010) in energetic terms. The interpretation of
BOLD signal is complicated by the dependence on underlying physio-
logical parameters including cerebral blood ﬂow (CBF), cerebral blood
volume (CBV) and vascular architecture, oxygen extraction fraction
(OEF) and cerebral metabolic rate of oxygen consumption (CMRO2).
The need to quantify brain activity better has driven recent methodo-
logical developments to measure oxygen metabolism in the brain as the
rate of oxygen consumption is closely linked to oxidative energy
release. CMRO2 therefore has the potential to be a useful biomarker
of the (patho)physiological state of brain tissue (Lin et al., 2010).
A number of diﬀerent MR-based methods for absolute CMRO2
http://dx.doi.org/10.1016/j.neuroimage.2017.03.028
Received 5 August 2016; Accepted 15 March 2017
⁎ Corresponding author.
E-mail address: wiserg@cardiﬀ.ac.uk (R.G. Wise).
NeuroImage 155 (2017) 331–343
Available online 18 March 2017
1053-8119/ © 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/BY/4.0/).
MARK
measurement have been proposed in recent years. A group of techni-
ques, known as calibrated BOLD methods, aims to estimate CMRO2
from BOLD and arterial spin labelling (ASL) signals, exploiting
contrast induced by respiratory tasks and mathematical models
describing the complex relationship between oxygen metabolism,
BOLD signal and CBF in the brain. Recently, extensions of the original
approaches of Davis and Hoge (Davis et al., 1998; Hoge et al., 1999)
have been developed allowing the use of both hypercapnia and
hyperoxia induced CBF and BOLD signal changes within the same
experiment, to estimate venous deoxyhaemoglobin concentration and
thus OEF and absolute CMRO2 (Bulte et al., 2012; Gauthier and Hoge,
2012; Wise et al., 2013), an approach also known as dual calibrated
fMRI (or dual calibrated BOLD).
In this paper we aim to show how this dual calibrated experimental
methodology, combined with a forward modelling estimation approach
can be used to assess the eﬀects of a drug (caﬀeine) on the brain with
good spatial resolution. We utilise a randomised, double-blind, place-
bo-controlled study design to demonstrate the acute eﬀects of caﬀeine
ingestion in low to average caﬀeine consumers. In particular, our aim is
to characterize the eﬀects of caﬀeine on brain metabolism and
haemodynamics, quantifying the main underlying physiological para-
meters of interest.
Caﬀeine is a methylxanthine and is one of the most frequently and
widely consumed psycho-active substances. It is a non-selective
antagonist of the adenosine receptors, especially types A1 and A2
(both A2A and A2B) (Fredholm et al., 1999; Pelligrino et al., 2012),
inhibiting the release of excitatory neurotransmitters. This has two
independent consequences on neural activity and blood ﬂow. On the
one hand, by inhibiting the A1 receptors, it increases the neuronal
ﬁring rate (Fredholm et al., 1999). On the other hand, acting on the
A2A and A2B receptors located on blood vessels, it promotes vasocon-
striction and therefore leads to reduction in CBF (Kusano et al., 2010;
Pelligrino et al., 2010). Due to the non-speciﬁc binding of caﬀeine to
both types of receptors (A1 and A2), these eﬀects may vary depending
on the proportional expression of the two receptors in speciﬁc areas of
the brain (Laurienti et al., 2003). In particular, studies with autoradio-
graphy (Svenningsson et al., 1997) and PET (Bauer et al., 2003;
Fukumitsu et al., 2003; Ishiwata et al., 2005) found both receptors to
be heterogeneously distributed across tissue, with the A1 type more
abundant in caudate nucleus, striatum, thalamus and superﬁcial
cortical areas, and A2 in putamen, caudate nucleus and thalamus.
Caﬀeine has also been reported to elicit other eﬀects of psycho-
physical nature, such as increased anxiety, alertness and raised blood
pressure (Einöther and Giesbrecht, 2013; Smith, 2002). Caﬀeine
plasma concentration peaks between 30 and 45 min after ingestion
followed by a plateau of approximately 60 to 80 min (Fredholm et al.,
1999; Nehlig and Boyet, 2000) and is then characterized by a wide half-
life range typically between 2.5 and 10 hours depending mainly on age,
gender and weight (Fredholm et al., 1999; Magkos and Kavouras,
2005).
Due to the parallel eﬀect on both the neuronal and vascular
systems, caﬀeine can alter the coupling between CBF and CMRO2.
Converging evidence has been found with PET and MR techniques,
indicating a reduction in baseline CBF (Cameron et al., 1990; Field
et al., 2003) and an increase in task-induced fractional increase in CBF
for regular caﬀeine consumers (Chen and Parrish, 2009a; Griﬀeth
et al., 2011). Both CBF and BOLD induced cerebrovascular CO2
reactivity (CVR) changes are reported not to be signiﬁcant (Chen and
Parrish, 2009b; Vidyasagar et al., 2013). Contrasting results have been
found for the eﬀects on oxygen consumption. In fact, the most relevant
MR studies ﬁnd decreases in relative stimulus-induced changes in
CMRO2 (Chen and Parrish, 2009a; Griﬀeth et al., 2011), which then
translates into increased (Chen and Parrish, 2009) or unchanged
(Griﬀeth et al., 2011) measured BOLD contrast. Regarding absolute
oxygen metabolism, there is an insuﬃcient body of research to support
any speciﬁc direction of the eﬀect of caﬀeine, with increase
(Griﬀeth et al., 2011), non-signiﬁcant decrease (Yang et al., 2015)
and no change (Xu et al., 2015) in CMRO2 being reported. To our
knowledge no MR study has mapped grey matter OEF and absolute
CMRO2 after caﬀeine consumption.
Within the framework of a dual calibrated fMRI experiment, we
estimate the eﬀects of caﬀeine using a forward model recently devel-
oped in our lab (Germuska et al., 2016), that describes analytically the
contributions of CBF and of the measured end tidal partial pressures of
CO2 and O2 (PetCO2, PetO2 respectively) to the measured dual echo
GRE signal. With this method we are able to estimate quantitative
maps of four parameters across grey matter: OEF, CBF, CBF-related
CVR (deﬁned as the percent change in CBF due to CO2) and CMRO2. In
parallel to these, measures of CBF and tissue arrival time (TAT) are
provided, by multi-inversion time ASL (mTI-ASL) acquisitions.
Materials and methods
Participants and caﬀeine administration
Sixteen healthy caﬀeine consumers (8 males, age=24.7 ± 5.1) were
recruited to the study. Exclusion criteria paid particular attention to
respiratory tasks (asthma, smoking, cold/ﬂu) and to potential interac-
tions with caﬀeine eﬀects (drug dependency, regular medications
altering systemic haemodynamics, prior negative reaction to caﬀeine).
Volunteers’ tolerance of hypercapnic periods and breathing through a
face-mask was tested with a non-MRI session held in the days before
the ﬁrst MRI scanning session. Caﬀeine intake was assessed with a self-
reported retrospective log of weekly caﬀeine consumption that quanti-
ﬁed the use of coﬀee, tea, cola, chocolate and other caﬀeine-containing
drinks, dietary supplements and over the counter medications
(Addicott et al., 2009). Volunteers that were low to moderate caﬀeine
consumers (between 51 and 298 mg/day, mean 154.1 ± 76.2 mg/day),
did not match exclusion criteria and successfully undertook the non-
MRI session were included in the study. The study was approved by the
local ethics committee. Written informed consent was obtained from
each participant.
Participants were asked to abstain from caﬀeine containing drinks,
food, pharmaceuticals and alcohol from the evening before the scan-
ning day (9 pm) and to have a light meal not later than one hour before
the visits to our lab. The caﬀeine dose administered was 250 mg
(roughly equivalent to the caﬀeine present in 2 cups of ground coﬀee),
chosen not to exceed the recommended daily limit to avoid adverse
eﬀects in low to moderate users (300 mg, Fredholm et al., 1999). This
is consistent with quantities used in previous studies, typically ranging
between 200 and 300 mg (Perthen et al., 2008; Vidyasagar et al., 2013;
Yang et al., 2015). The choice of excluding high consumers and
caﬀeine-naïve volunteers was made to maximize the chance of avoiding
strong withdrawal eﬀects and unexpected reactions to caﬀeine respec-
tively.
Experimental design
Fig. 1 illustrates the experimental design. Each participant was
scanned on two diﬀerent days (30.1 ± 18.8 days apart, same time of the
day), each day including the same protocol with a pre-dose scan session
followed by the delivery of the capsule of drug or placebo (randomized
order for males and females) and ﬁnally a post-dose scan session.
The pre-dose sessions included an anatomical T1-weighted scan
(when not already available for the participant) then a multi inversion
time ASL (CBF) scan (mTI scans) and a dual calibrated fMRI scan
(dcFMRI scan), giving a duration of about 40 min. The post-dose
sessions instead included a mTI CBF scan followed by a dcFMRI scan
and ﬁnally another mTI CBF scan, giving a total duration of about
50 min.
Each dcFMRI scan contained an 18 min respiratory task, with
interleaved periods of hypercapnia, hyperoxia and medical air being
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delivered to the subjects according to the optimized protocol previously
proposed by our lab (Germuska et al., 2016).
At the end of the ﬁrst scan session the subjects were removed from
the MRI scanner and given a capsule containing either 250 mg of
powdered caﬀeine or placebo (cornﬂour). Caﬀeine was administered in
a double-blind, crossover, placebo-controlled, randomised manner.
This was followed by a 30 min pause for the caﬀeine absorption,
during which the subjects were allowed to relax and consumed nothing
other than water. After this time, they were led back to the MR suite for
the post-dose scanning session. Based on the reported drug kinetics
(Fredholm et al., 1999), we expected the plasma levels of caﬀeine to
stay approximately stable for the duration of the second dcFMRI
acquisition, that started about 45 minutes after the capsule adminis-
tration.
At the beginning and end of each scanning day, volunteers were
asked to ﬁll in a Mood and Physical Sensations Scale questionnaire
(MAPSS), in order to evaluate their mental and physical state (Rogers
et al., 2010).
Salivary samples
A total of 6 salivary samples (3 for each day) was taken from each
volunteer in order to assess the caﬀeine content of saliva over time, an
index of plasma caﬀeine level (Fredholm et al., 1999). The sample
consisted of a swab (Salivette®) that the participants chewed for one
minute. Before the ﬁrst sample, subjects were asked to rinse their
mouth with water in order to reduce contamination. On each scanning
day samples were taken pre-dose and approximately 30 and 60 min-
utes post-dose (“pre”, “post1” and “post2” respectively, see Fig. 1).
Respiratory task
The respiratory task followed the optimized design proposed by our
lab (Germuska et al., 2016), with three periods of hypercapnia
interleaved with two periods of hyperoxia similarly to interleaved
paradigms adopted in other studies (Bulte et al., 2012; Wise et al.,
2013), for a total duration of 18 minutes (see Fig. S-1,C). In order to
achieve hypercapnia, ﬁxed inspired values of CO2 (5%) were adminis-
tered. To achieve hyperoxia 50% O2 was administered. In addition
short periods of respectively 100% O2 (14 s) and 10% O2 (40 s) were
used in order to accelerate the transition to hyperoxia and the
subsequent return to normoxia. The short duration of hypoxic mixture
inhaled did not induce arterial hypoxia. Supplies of 5% CO2 (balance
air), 10% O2 (balance N2), 100% O2 and medical air were delivered at a
total ﬂow rate of 25 l/min to the gas mixing chamber which was placed
in the MR control room and connected to the breathing circuit through
a humidiﬁer. An independent O2 backup cylinder was also connected
directly to the breathing circuit for safety reasons.
The gas delivery system consisted of a laptop personal computer
using in-house Matlab software (Mathworks, Natick, MA, USA) to
control the voltage output from a NI-DAQ AD converter (National
Instruments, Austin, TX). The output voltages were then fed into four
mass ﬂow controllers (MKS Instruments, Wilmington, MA, USA) that
administered the gas at the required ﬂow rate. The respiratory circuit
adopted was based on that of Tancredi and colleagues (Tancredi et al.,
2014). Gas levels were sampled from the volunteer's facemask and tidal
partial pressures of O2 and CO2 were measured and recorded using
rapidly responding gas analysers (AEI Technologies, Pittsburgh, PA,
USA).
fMRI data acquisitions
Scanning was performed on a 3 T GE HDx MRI system (GE
Healthcare, Milwaukee WI) with a body transmit coil and 8-channel
head receive coil. All participants underwent (or had available) whole
brain T1-weighted structural scans (3D FSPGR, 1×1×1 mm voxels, TI/
TR/TE=450/7.8/3 ms).
For the mTI pulsed ASL acquisition, dual-gradient echo (GRE)
readout and spiral k-space acquisition imaging was used with the
following acquisition parameters: TE1=2.7 ms, TE2=29 ms, ma-
trix=64×64, voxel size=3x3×7 mm3, slice gap=1 mm, 12 slices.
Automated linear shimming with the built-in software (GE HDx) was
performed. Perfusion weighting on the two scans included four equally
spaced inversion times each: 150, 300, 450, 600 ms (sh. mTI in Fig. 1)
and 1000, 1400, 1800, 2200 ms (lo. mTI in Fig. 1). The proximal
inversion and control for oﬀ-resonance eﬀects (PICORE) tagging scheme
was used with a quantitative imaging of perfusion using a single
subtraction (QUIPSS II) cutoﬀ at 700 ms for TI > 700 ms. Label thickness
was 200 mm with a 10-mm gap between the distal end of the labelling
slab and the most proximal imaging slice. Variable repetition time was
used in both cases, such that imaging time was minimized. Twenty
control–tag pairs were acquired for each inversion time, resulting in a
total acquisition time of about 3.5 and 6 minutes respectively.
For the dcFMRI acquisition, simultaneous perfusion and BOLD
imaging data was collected using a PASL PICORE, QUIPSS II imaging
sequence with a dual-gradient echo (GRE) readout and spiral k-space
acquisition with the same acquisition parameters as the mTI scans,
except for the use of a single inversion time (TI2=1500 ms), a set
repetition time (TR=2.2 s) and acquiring 490-volumes (245 tag-control
pairs).
Fig. 1. Diagram of the experimental design. Capsule delivery consists of caﬀeine or placebo (order randomized with gender).
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All mTI and dcFMRI scans were preceded by two calibration scans.
The ﬁrst consisted of a single shot spiral k-space scan to estimate the
equilibrium magnetization of brain tissue (M0), used for perfusion
quantiﬁcation (Çavuşoǧlu et al., 2009), with the same acquisition
parameters as for the perfusion-weighted scans, except for being
acquired with fully relaxed magnetization and no labelling. The second
was a low resolution, minimal contrast image used for coil sensitivity
correction (Wu et al., 2011), with the same acquisition parameters as for
the equilibrium magnetization scan, except for TE=11 ms and TR=2 s.
Behavioural data
Mood, Alertness and Physical Sensations Scales (MAPSS) was used
to measure anxiety, alertness, and headache (Rogers et al., 2010). The
scale comprised 15 questions to which participants were instructed to
rate mood and physical sensation states according to how they were
feeling “at the moment” using an eight-point unipolar scale, where 1
represented ‘not at all’ and 8 represented ‘extremely’. Participants were
instructed: ‘There are no right or wrong answers. Do not spend too
much time on any one statement but give the rating which seems to
best describe your present feeling’.
Three aspects of mood were rated on unipolar scales: energetic
mood (sleepy–energetic), tense mood (tense–relaxed) and hedonic
tone (sad/gloomy–happy/cheerful). One item assessed mental alert-
ness. The physical sensation descriptors were clear-headed–muzzy/
dazed, light-headed/ feeling faint, jittery/shaky, and headache.
The code used in this manuscript is openly available from the
Cardiﬀ University data archive http://dx.doi.org/10.17035/d.2016.
0008251305. However, due to ethical considerations open access
cannot be given to the in vivo subject data or data derived from this.
Data analysis
dcFMRI data and end-tidal traces
dcFMRI data were pre-processed with motion correction
(MCFLIRT (Jenkinson et al., 2002)) and brain extraction (Smith,
2002) and spatially smoothed with a Gaussian kernel of 6 mm with
SUSAN (Smith and Brady, 1997), separately for echo 1 and echo 2.
Calculation of physiological parameters of interest was performed with
a Bayesian framework of analysis applied to the forward model
previously developed in our lab (Germuska et al., 2016), whose
deﬁning equations are reported in the Appendix for reference. For
the purpose of this study, the estimated scaling parameter K is
considered as a lumped parameter, with no explicit physiological
connotation (see Eq. A-2 in the Appendix). This is justiﬁed by the
parametrisation of the model according to that previously proposed by
our centre (Merola et al., 2016), that only allows us to model K in a
numerical fashion. The Gaussian priors on estimates were deﬁned
specifying means and standard deviations (mean,std.) as
OEF=(0.35,0.1), CBF=(60,Inf) ml/100 g/min, CVR=(3,0.774)
%/mmHg, K=(0.07,0.087), where by “Inf” we mean a non-informative
prior. Non-informative priors are used to initialize the estimate without
carrying information, therefore they can be thought of as uniform
distributions of probability. No prior is deﬁned on the estimates of
CMRO2 as this is calculated as CMRO2=CBF·OEF·CaO2, where CaO2 is
the arterial concentration of oxygen. Other parameters were kept the
same as those reported in the original work (Germuska et al., 2016).
The inputs to the framework are dual echo GRE images and, PetO2 and
PetCO2 traces, then analytic models describing the magnetization
decay occurring at the ﬁrst and second TE were used to estimate grey
matter maps of OEF, CBF, CVR and CMRO2. Prior to analysis, the end-
tidal responses were visually aligned with the MR data to remove the
inﬂuence of any bulk delay between the recorded end-tidal traces and
the fMRI data. The resulting maps were registered into anatomical
space and ﬁnally to MNI space (using FSL FLIRT, (Jenkinson et al.,
2002)) for second level analysis.
Mean grey matter values of each estimated parameter were
calculated for the four scans and masked for I) partial volume grey
matter values (based on MNI space priors) greater than 30% and then
II) estimated values of CBF within the range [0 200] ml/100 g/min.
The ﬁrst criterion was imposed as an empirical threshold to avoid
values aﬀected by poor SNR of the signal in white matter, while the
second was used to exclude non-physiological values. Moreover results
from one subject (s16) were excluded for their poor quality in a single
acquisition, with abnormally unsteady end-tidal values due to the very
irregular breathing pattern that made estimation unfeasible. Therefore
the subsequent statistical analyses were carried out on N=15 subjects.
T-tests were used to examine the signiﬁcance of diﬀerences between
caﬀeine and placebo in the percentage change of estimated parameters
from pre to post condition.
Group-level voxel-wise analyses were performed. For each para-
meter the diﬀerences from pre to post condition with placebo were
tested against those obtained with caﬀeine with a paired t-test. In order
to do this, anatomical T1-weighted images were ﬁrst registered to the
MNI152 standard space with the FSL program FNIRT (Andersson
et al., 2007) and the obtained transformations were then applied to the
estimated maps. T statistics were then calculated on the map in MNI
152 standard space with the AFNI program 3dttest++ (Cox, 1996) and
thresholded with a voxel-wise signiﬁcance level of αv=0.01 and a
cluster-wise level of αc = 0.05 with minimum size of 246 mm
3, as
estimated with the AFNI program cdf (Cox, 1996).
In addition, a ROI analysis was carried out to further investigate the
spatial distribution of the estimated parameters at a group level. Mean
changes in estimated parameters from pre to post condition in caﬀeine
and placebo are reported for seven diﬀerent ROIs: caudate nucleus,
frontal lobe, insula, occipital lobe, parietal lobe, putamen and thala-
mus. For this analysis the issue of multiple comparisons between ROIs
was dealt with a false discovery rate (FDR) correction (Benjamini and
Hochberg, 1995), which allowed us to control the expected proportion
of falsely rejected hypotheses.
Multiple inversion time ASL data
Data were analysed using a two-compartment model developed by
Chappell and colleagues (Chappell et al., 2010) which attenuates the
error in CBF estimates due to signal arising from intravascular blood by
modelling its eﬀect on the ASL signal. In particular, the oxford_asl
program – included in the FSL BASIL toolkit – was used, allowing us to
obtain unscaled CBF maps, along with estimated arterial blood volume
(aCBV, if found to signiﬁcantly contribute to the signal) and tissue
arrival time (TAT). CBF quantiﬁcation and coil sensitivity correction
were then performed as for the dcFMRI data.
Mean grey matter values of CBF and TAT were calculated for the six
scans and masked following the same criteria adopted for the dcFMRI
data. Note that in this case the factor measurements were taken in
three time points (“pre”,”post1” and “post2”).
Finally t-tests were performed voxel-wise for CBF and TAT to
localise possible spatial distributions of the caﬀeine eﬀects as per the
dcFMRI data. The registration of the maps from subject space to
MNI152 standard space was carried out with FNIRT (Andersson et al.,
2007), while t statistics were calculated with the AFNI program 3dttest
++ (Cox, 1996) and thresholded with a voxel-wise signiﬁcance level of
αv=0.01 and a cluster-wise level of αc=0.05 with minimum volume size
of 246 mm3. For ease of comparison with the results obtained from
dcFMRI data, t-tests were only performed with diﬀerences between the
pre and post2 condition.
In addition to calculating CMRO2 from the single inversion time
ASL acquisition CBF estimates during dcFMRI, CMRO2 was also
calculated using Eq. A-10 from the multiple inversion time CBF
estimates, yielding CMRO2,mTI.
Behavioural data
Two-way ANOVA tests were performed for each of the 15 items of
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the MAPPS, to test for diﬀerences in the eﬀect of the two factors
considered, that is 1) “drug” (i.e. caﬀeine or placebo) and 2) “dosing”
(i.e. pre or post dose).
Results
Salivary sample data
Concentrations of caﬀeine from the salivary samples are reported
for all subjects in Fig. 2. These show that the levels of caﬀeine in saliva
are signiﬁcantly diﬀerent from baseline (“pre” condition) at thirty
minutes post caﬀeine ingestion and continue to rise from a mean of
2.08 mg/l to a signiﬁcantly higher mean value of 4.1 mg/l between
post-caﬀeine 1 and post-caﬀeine 2 samples. Concentrations remain
constantly low for placebo.
dcFMRI data and respiratory traces
The end-tidal traces for a single representative subject (s12), the
end-tidal traces averaged across all subjects and the respiratory task
can be found in the supplementary material (Fig. S-1). The average
baseline PetO2 value was 113 mmHg, while it was 39 mmHg for
PetCO2. The average change in PetCO2 from baseline was 12 mmHg
during hypercapnia, while plateau levels of hyperoxia caused an
average increase of approximately 211 mmHg in PetO2. Subject (s16)
was excluded due to and irregular breathing pattern and subsequent
poor end-tidal traces (data not shown).
Grey matter mean values of all the estimated parameters for the
four conditions considered are reported in Fig. 3. Changes from “pre”
to “post” conditions are not found to vary signiﬁcantly for any
parameters for placebo administration. By contrast, with caﬀeine a
signiﬁcant increase is found for OEF and CVR, with values changing
form 0.42 ± 0.067 to 0.48 ± 0.066 (Fig. 3, A) and from 2.2 ± 0.50 to 2.5
± 0.36 (Fig. 3, C) %/mmHg respectively. Also, with caﬀeine signiﬁcant
decreases are found for CBF and CMRO2, with values changing from
65 ± 12.3 to 45 ± 6 (Fig. 3, B) ml/100 g/min and from 233 ± 48.3 to
188 ± 35.9 (Fig. 3, D) μmol/100 g/min respectively. Finally in Fig. 3, E,
results for CMRO2 calculated using the CBF estimates obtained from
the mTI (CMRO2,mTI) analysis is shown to signiﬁcantly decrease from
173 ± 29.2 to 134 ± 31 μmol/100 g/min. For completeness, calculated
grey matter values (mean and standard deviation) for all the physio-
logical parameters can be found in the supplementary material (Table
S-2 and S-3).
Fig. 4 shows the mean grey matter percent change from the pre to
post condition for all parameters in the caﬀeine and placebo sessions.
Diﬀerences between the percent changes between the two sessions are
found signiﬁcant in a paired t-test for OEF, showing an increase of
15.6% (sd ± 18.9%, p < 0.05), and CBF, CMRO2 and CMRO2,mTI
showing a decrease of −30.4% (sd ± 6.1%, p < 0.01), −18.6% (sd ±
11.1%, p < 0.01) and −22.3% (sd ± 14.7%, p < 0.05) respectively
following caﬀeine consumption.
Figs. 5 and 6 show results from voxel-wise analysis of the estimated
cerebral physiological parameters. In Fig. 5 are examples of grey matter
values of estimated maps registered to MNI152 standard space for a
single representative subject (s12) before and after caﬀeine consump-
tion (“pre” and “post” condition respectively). These maps are con-
sistent with the mean trend, with values of CBF and CMRO2 generally
decreasing while values of OEF and CVR are increasing. Besides they
are representative of the variability of the result, with generally
spatially smooth results for OEF as opposed less smooth estimates
for CVR. In these maps it is also possible to see areas where the
algorithm fails in its estimates (indicated by arrows in Fig. 5).
Fig. 6 displays thresholded t values from the group t-test performed
between the diﬀerences from pre to post condition with caﬀeine and
placebo. Areas of signiﬁcant change are found for all parameters. More
information on the size and coordinates of these for OEF and CMRO2
can be found in the supplementary material (Table S-4 and S-5). CBF
shows widespread and highly signiﬁcant decrease due to caﬀeine.
CMRO2 also shows areas of signiﬁcant decrease, but they are more
localized. Conversely, results from OEF and CVR indicate areas of
increase due to caﬀeine, with the latter being conﬁned to only few
signiﬁcant areas. None of the parameters showed mixed directions of
signiﬁcant eﬀects.
Finally, Fig. 7 shows the results of a ROI analysis to further
investigate the spatial distribution of the estimated parameters at a
group level. Mean changes from pre to post condition in caﬀeine and
placebo are reported for seven diﬀerent ROIs. These show the eﬀect of
caﬀeine being consistently signiﬁcant for CBF (Fig. 7, B), while being
more varied for the others. OEF (Fig. 7, A) changes are signiﬁcant in
the caudate nucleus, putamen and thalamus (ROIs 1, 6 and 7). CVR
does not show signiﬁcant eﬀects, with measurements characterized by
high variance across regions. Finally, decreases in CMRO2 (Fig. 7, D)
are only signiﬁcant in occipital lobe and parietal lobe (ROIs 4 and 5).
Values of CMRO2,mTI (Fig. 7, E) conﬁrm these ﬁndings and also
highlight a signiﬁcant decrease in the frontal lobe (ROI 2).
Multiple inversion time haemodynamic estimates
Mean grey matter values of all the estimated CBF and TAT for the
six conditions considered are reported in Fig. 8. Changes from baseline
are not found signiﬁcant for placebo. Instead, in caﬀeine a signiﬁcant
decrease (p < .01) is found for CBF from 49 ± 8.9 ml/100 g/min before
caﬀeine delivery to 34 ± 5.6 ml/100 g/min after thirty minutes and
then to 32 ± 5.2 ml/100 g/min after sixty minutes. Also the last two
show a signiﬁcant diﬀerence, even though less strong (0.01 < p < 0.05).
TAT values for caﬀeine show a signiﬁcant increase from 0.71 ± 0.038 s
in the pre to 0.74 ± 0.029 s at post1 and then to 0.74 ± 0.028 s at post2.
Finally in Fig. 9 t statistics resulting from a group-level test
performed between diﬀerences from pre to post2 condition in caﬀeine
and placebo are reported. CBF shows a general signiﬁcant decrease
across grey matter. TAT shows more restricted areas of signiﬁcance,
with both a positive and negative direction of change.
Behavioural data
The analysis of behavioural data showed no signiﬁcant eﬀects of
caﬀeine, with the highest F value (F=6.22, p=0.015) indicating a
decrease in feeling relaxed after having ingested the capsule (p value
not signiﬁcant when corrected for multiple comparisons). Mean
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changes from pre to post condition show a non-signiﬁcant trend of
caﬀeine reducing sleepiness, fatigue and headache while increasing
energetic mood and jitteriness compared to placebo. These results are
shown in the supplementary material section (Table S-6).
Discussion
We have shown a generalised eﬀect of a 250 mg dose of caﬀeine across
cerebral grey matter to decrease CMRO2 (−19± 3 mean±SEM%) using
dual calibrated fMRI and a forward modelling approach to parameter
estimation. The measured CMRO2 decrease is the net result of two
competing observations: substantial decreases in CBF (30% reduction)
and fractionally smaller increases in OEF (16%) that partially counteract
the reduced oxygen delivery to the capillary bed. The haemodynamic
ﬁndings, a reduction in CBF, conﬁrm earlier reports (Cameron et al.,
1990; Field et al., 2003). The reduction in the rate of cerebral oxygen
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metabolism contrasts with reports from some other MRI studies that
show both increases (Griﬀeth et al., 2011) and no change (Xu et al., 2015)
in CMRO2, while it is consistent with other recent ﬁndings reporting a
decrease, using simultaneous near-infrared spectroscopy and transcranial
Doppler ultrasound (Yang et al., 2015), and FDG-PET (Park et al., 2014).
However, the latter study only reports localised reductions in relative
cerebral glucose metabolism (CMRGlu). Furthermore, reductions in
CMRGlu are not certain to lead to reductions in CMRO2 as alterations
in aerobic glycolysis (Vaishnavi et al., 2010) could lead to diﬀerences in
the degree to which CMRO2 and CMRGlu change with caﬀeine admin-
istration.
The reduction in CMRO2 found lies at the upper end of what one
might expect to see with a commonly consumed substance that does
not have a profound eﬀect on consciousness. However, the reduction in
CMRO2 is considerably smaller than for interventions causing sub-
stantial suppression of electrophysiological activity, such as, anaes-
thetics and hypothermia (−52% for etomidate in dogs (Milde et al.,
1985); −44% for propofol in humans (Newman et al., 1995); −58% for
−8 °C hypothermia in humans, (Newman et al., 1995); −64% for
−10 °C hypothermia in humans (Croughwell et al., 1992)).
The observations of reduced CMRO2 are somehow counterintuitive
when considering the known eﬀects of caﬀeine on neuronal activity. In
fact, the increase in neuronal ﬁring produced by caﬀeine might be
expected to yield an overall increase in the energetic metabolism. A
possible explanation for our results can be oﬀered by a hypothesis of
decrease in energetic demand due to a net inhibitory eﬀect of caﬀeine.
In fact, as caﬀeine disinhibits both excitatory and inhibitory neurons,
alterations of the total energy demand can result from changes in the
local balance between the activity of the two populations (Buzsáki et al.,
2007; Logothetis, 2008). This means that while, in areas dominated by
excitatory activity, the energy demand might be unaltered (or even
increased), the energy demand overall might decrease where the
inhibitory activity substantially down-regulates excitatory activity. A
key role in this mechanism is likely to be played by the diﬀerent
aﬃnities of adenosine receptors and their spatial distribution
(Fredholm et al., 1999; Laurienti et al., 2003; Pelligrino et al., 2012).
As the caﬀeine dose used in this study is relatively high, a dose
dependent mechanism might also modulate these processes, although
further investigation would be needed to explore such eﬀects. The
hypothesis of a decrease in energetic demand is also partially supported
by previous electrophysiology studies ﬁnding reductions in spectral
power with EEG (Dimpfel et al., 1993; Siepmann and Kirch, 2002) in
the resting state following caﬀeine ingestion.
In particular, the overall inhibitory eﬀect found could be mediated
by two distinct mechanisms reportedly induced by caﬀeine as an
antagonist of adenosine receptors: pre-synaptic inhibition of neuro-
transmitter release and prevention of post-synaptic depression
(Pelligrino et al., 2012). The result of the two would be a decrease in
synaptic activity accompanied by increase in spiking activity, the latter
being a known result of the caﬀeine interaction with A1 receptors
(Fredholm et al., 1999). As the metabolic demand of the ﬁrst is
predominant in the total energetic balance of neural activity (Raichle
and Gusnard, 2002), a decrease in oxygen metabolism might be
expected to result from caﬀeine.
As grey matter maps were estimated for all parameters, we were
able to carry out voxel- and ROI-wise analyses at a group level in order
to investigate the spatial distribution of the caﬀeine eﬀects. The
signiﬁcant caﬀeine eﬀects were widespread for CBF (single and
multi-TI ASL data), as expected due to adenosine receptors being
widespread over all grey matter. Areas of signiﬁcant caﬀeine eﬀect were
instead more restricted for OEF, CMRO2 and CVR. Notably, in the ROI
analysis, signiﬁcant changes in OEF were localized to the putamen,
caudate nucleus and thalamus, where the highest concentrations of A1
and especially A2 receptors have been reported (Svenningsson et al.,
1997; Fukumitsu et al., 2003; Ishiwata et al., 2005). These regions
show the least diﬀerence in CMRO2 between pre and post dose, with
values not signiﬁcantly diﬀerent between the two conditions. This
behaviour, conﬁned to a few subcortical structures, is in contrast with
the general grey matter tendency and may reﬂect the spatially varying
eﬀects of the A1 and A2 receptors and their relative expression in these
speciﬁc areas (Laurienti et al., 2003) and possibly representing the
above mentioned areas of local inhibitory activity triggered by caﬀeine.
While the neuro-pharmacological origins of such an eﬀect deserve
further investigation, the ﬁndings suggest a complex and spatially
distributed eﬀect across grey matter that can be characterised with our
novel approach, while it cannot be properly captured with bulk
measurements or imaging methods that look only at whole brain
oxygenation (Xu et al., 2015).
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Results for group mean grey matter seem to be overestimating
CMRO2 when compared to literature, with a resting state value of
242.4 ± 38.4 μmol/100 g/min (averaging the results from pre condition
in each day) opposed to reported values of 145 ± 30 (Gauthier and
Hoge, 2011) and 155 ± 39 μmol/100 g/min (Bulte et al., 2012)
obtained with calibrated BOLD methods and values of 182 ± 12 (Liu
et al., 2013), 158 ± 18 (Fan et al., 2012) and 125 ± 15 μmol/100 g/min
(Bolar and Rosen, 2011) obtained with other MR methods and of
157.4 ± 19.7 (Roland et al., 1987) and 120 ± 17.7 μmol/100 g/min
(Ibaraki et al., 2010) with PET. This overestimate can in part be
explained by the young cohort analysed, but can be mostly attributed to
the propagation of systematic bias in estimates of CBF from the single
inversion time data. In fact our baseline grey matter CBF estimates are
65.8 ± 11.7 ml/100 g/min (averaging the results from pre condition in
each day), similar to values of 63 ml/100 g/min reported in other
studies with a similar type of single TI acquisition (Ances et al., 2009),
whereas typical literature values range between 41 ml/100 g/min
(Bulte et al., 2012) and 52 ml/100 g/min (Gauthier and Hoge, 2011).
Our estimates of caﬀeine-induced CBF changes obtained with dcFMRI
acquisitions (single TI) are supported by the data from mTI-ASL
acquisitions. A similar decrease of 30 and 35% is found when
comparing the value in pre to post1 and post2 conditions respectively
(Fig. 8) and a good correlation is found between the two sets of
measurements obtained with the diﬀerent acquisition approaches (data
not shown). However, there is an approximately constant oﬀset
between the two estimates, with those obtained from our forward
model being about 15 ml/100 g/min higher than those obtained with
the mTI model. Estimates from single TI measures, as in the case of the
forward model, tend to overestimate CBF compared to those from
multi TI measures, due to both assumed constant timings of the
labelled bolus (Van Osch et al., 2007) and spurious arterial signal
contribution to the ASL signal (Chappell et al., 2010). The overestimate
of CBF is likely to explain the high values of CMRO2 that we estimate
(as by deﬁnition CMRO2=CBF·OEF·CaO2). In fact, CMRO2,mTI esti-
mates based on the mTI CBF data show mean values of about
182 μmol/100 g/min in the pre-dose condition, which is more similar
to values reported in the literature. Nevertheless, as changes in CBF are
consistent between the single and multi TI techniques, our method still
enables us to detect drug related changes in CMRO2.
Caﬀeine salivary concentrations suggest that subjects generally
complied with the request of abstaining from caﬀeine consumption
before the experiments. Caﬀeine saliva concentration increased sig-
niﬁcantly from post1 to post2. However, there is variability in the
temporal proﬁle of caﬀeine salivary concentrations that may reﬂect
diﬀerent absorption and elimination kinetics. Time to peak values are
reported to be between 30 and 45 minutes (Fredholm et al., 1999).
Post1 mTI-ASL acquisitions might be measuring a changing haemody-
namic state of brain tissue, leading to noisier estimates of CBF and also
values of CBF signiﬁcantly diﬀerent between post1 and post2 conditions
(as seen in Fig. 8). On the other hand we do not expect the
haemodynamic state to change greatly for the subsequent post
dcFMRI acquisitions thanks to the experimental timing.
Data fromMAPPS reports did not show signiﬁcant eﬀects of drug or
dosing on the psycho-physical state of the participants. Nevertheless
there were non-signiﬁcant trends indicating that caﬀeine reduces
sleepiness, fatigue and headache and increased energetic mood and
jitteriness compared to placebo, which is consistent with eﬀects
reported in literature for larger groups of participants (Rogers et al.,
2010; Smith et al., 2012). Importantly, values measured with MAPSS
and feedback from subjects did not indicate signiﬁcant adverse
reactions to caﬀeine consumption that could have caused discomfort
to the subjects and therefore behaviour capable of degrading the
quality of the data (e.g. movements into the scanner).
The analysis and results presented in this work have some limitations
worth noting. The ﬁrst relates to the assumptions that we make when
modelling the physiological processes of interest. Of primary importance
Fig. 6. Results of a group t-test performed between diﬀerences from “pre” to “post” condition in caﬀeine and placebo for the dcFMRI data. Each map shows values of the t statistic for
which p < 0.01 either in positive or negative direction (t > 3.33 and t < −3.33 respectively, 14 dof), with thresholding for cluster size signiﬁcance level αc=0.05).
A. Merola et al. NeuroImage 155 (2017) 331–343
338
is the hypothesis of isometabolism during hypercapnia and hyperoxia
when performing respiratory tasks. The eﬀects of its violation have been
investigated and characterised in a previous study from our centre
(Merola et al., 2016). Similarly, we also assume that metabolism does
not change during the dcFMRI acquisitions. This may not be the case in
the post condition of the caﬀeine day due to possible changes of caﬀeine
plasma concentration, although literature knowledge suggests that the
concentration plateaus by the time the acquisition starts (Fredholm
et al., 1999). In addition, the value of θ in our signal model is ﬁxed as per
the optimisation previously carried out in our centre (Merola et al.,
2016) and assumed not to change across subjects, tissue or conditions.
In reality θ could vary and may be estimable with additional experi-
mentation, similarly to what has been proposed for estimating values of
α and β (as show in (Chen and Pike, 2009) and (Shu et al., 2016)
respectively). However, we took a pragmatic approach of ﬁxing θ as a
trade-oﬀ between the complexity of our acquisition and the sensitivity to
the underlying physiological variability. In fact, analogous assumptions
of α and β have been made for a successful body of calibrated BOLD
studies. Part of this success is related to the fact that despite the
parameters α and β of the Davis model (Davis et al., 1998) being not
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necessarily homogeneous across the brain or diﬀerent conditions, the
physiological model is still able to eﬀectively explain the relationship
between BOLD, CBF and CMRO2, as found by diﬀerent groups and well
summarised by Griﬀeth and Buxton (Griﬀeth and Buxton, 2011).
The choice of the parameter θ also results into the deﬁnition of K as
a lumped parameter, which is dependent, among other things, on the
baseline cerebral blood volume. Nevertheless, it is worth noting that
this formulation results in unbiased estimates of OEF, as found in a
previous study from or centre (Merola et al., 2016).
Another limitation is represented by the reliability of individual
results. In fact, while values of the parameters averaged across grey
matter lie within physiological ranges and show generally plausible
trends (as seen in Fig. 3), individual maps include several outliers
(Fig. 5). This is mainly due to low SNR of the MR signal and variability
of the respiratory traces, which tend to bias or even prevent the
estimates in some voxels. If this represents a shortcoming on one hand,
on the other hand it demonstrates that the estimates are not driven by
Bayesian priors as also suggested by the existence of limited areas
where the method fails to output valid values (highlighted in Fig. 5). At
current SNR levels in the acquisition, this limits the use of the
technique to group analysis, for which it is still possible to detect areas
of signiﬁcant drug eﬀect both in a voxel-wise and ROI-wise manner. A
trade-oﬀ between repeatability and spatial resolution has to be
considered when comparing our estimates to bulk measurements of
fewer parameters. In fact, this represents the ﬁrst MR approach
supplying a detailed description of the acute eﬀects of caﬀeine on
brain metabolism and haemodynamics with grey matter maps of OEF
and absolute CMRO2 values.
A SNR limitation also prevents measurements across white matter,
where the signal is lower mainly due to the reduced cerebral blood ﬂow
and longer arrival time of the arterial spin label. In principle, with a
better SNR, the estimation framework could also be applied to white
matter following few modiﬁcations; for example the physiological
model relating BOLD and ASL signals to oxygen metabolism would
need to be optimised for the new context. Potential improvements
could be introduced with higher magnetic ﬁelds, head receive coils with
higher number of channels or background suppression techniques.
Finally some caution in the interpretation of the results is more
speciﬁcally related to the caﬀeine eﬀects we are characterizing with the
Bayesian estimation framework. Because CMRO2=CBF·OEF·CaO2,
detection of changes in CMRO2 might simply be triggered by decreases
in CBF with little or no change in OEF. This could be the case, for
example, if the model was highly sensitive to changes in CBF but less so
to changes in OEF. However, the fact that areas where signiﬁcant
changes in CBF and OEF occur at the same time are showing no
signiﬁcant change in CMRO2 argues against this suggestion (see
caudate nucleus, putamen and thalamus in Fig. 7).
In conclusion, we have characterised acute eﬀects of caﬀeine on brain
haemodynamics and oxygen metabolism with the forward signal model in
a drug study with a dual calibrated fMRI experiment. The caﬀeine eﬀects
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measured of reduced oxygen consumption and cerebral blood ﬂow are
consistent with those from neurophysiological studies and previous
studies of caﬀeine haemodynamics. New information is provided in terms
of spatial distribution of the drug eﬀects on OEF and CMRO2 allowing us
to identify particular areas where the drug eﬀects are localized. This
represents a major step forward in the understanding of the acute eﬀects
of caﬀeine and it also demonstrates that such a method could be applied
to assess grey matter haemodynamics, OEF and CMRO2 at a voxel-wise
resolution for other pharmacological agents.
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Appendix
The Bayesian estimation framework used in this work (Germuska et al., 2016) is based on a forward signal model constructed by combining a
detailed description of the arterial spin labelling (ASL) signal developed by Woolrich and colleagues (Woolrich et al., 2006) and a model of the
BOLD model developed in our centre (Wise et al., 2013). Computationally, the model exploits a Matlab toolbox for variational Bayesian approaches
(VBA) developed and made available by Daunizeau and colleagues (Daunizeau et al., 2014). Here we summarize the equations relating the
estimated parameters OEF, CBF, CVR and CMRO2. For a detailed description of the model please refer to the original paper (Germuska et al.,
2016), while the code used for the estimates is available in the Cardiﬀ University data Catalogue at http://dx.doi.org/10.17035/d.2015.100126.
The total MR signal STOT resulting from a dual-gradient echo (GRE) imaging sequence with a PASL PICORE, QUIPSS II scheme for ASL signal
can be expressed as:
S S e=TOT ASL TER R R− * (1+∆ */ * )2,0 2 2,0 (A-1)
Where SASL is the ASL signal and the BOLD contribution is accounted for by changes in transverse relaxation rate R2
*. As regards the latter, it can be
expressed following the model ﬁrst proposed by Wise and colleagues (Wise et al., 2013) and then optimised (Merola et al., 2016) as:
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Where [dHb] is the deoxy-haemoglobin concentration (0 for baseline), PaCO2 is the arterial partial pressure of O2, CVR is the cerebrovascular
reactivity (in %ΔCBF/mmHgCO2), θ is an optimised ﬁtting parameter and K is a lumped parameter depending on cerebral blood volume, ﬁeld
magnitude, echo time and geometry. Then OEF can be calculated from the expression for [dHb]/[dHb]0 proposed by Wise and colleagues (Wise
et al., 2013):
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Where [dHb] is the haemoglobin concentration, φ is the O2 carrying capacity of haemoglobin (1.34 ml O2/gHb) and CaCO2 is the arterial O2 content.
The ASL contribution SASL can also be expressed, following Woolrich model (Woolrich et al., 2006), as a sum of a static component (Ss) and a
component due to perfusion (Sb):
S S S= +ASL s b (A-5)
Where the static component is expressed in terms of changes in voxel magnetization M:
S M M M= (1 + ∆ / )s 0 0 (A-6)
So that changes in M0 are assumed to derive from a change in blood volume and water exchange. The perfusion component is then expressed in
terms of changes of CBF and the kinetic PASL model:
S M CBF CVR PaCO TI P e e TI TI δt e δt= · · (1 + · ∆ /100) · {[ · ( + (1 − ))] + [( − − ) · (1 − + )]}b blood o n TI T TI T TI TI T0, 2 1 − / − / 2 1 −( − )/b b b2 1 2 1 2 1 1 (A-7)
Where M0,blood and T1b are respectively the baseline magnetization and the longitudinal relaxation time of blood, Pn is −1 for tag and 1 for control
and ﬁnally TI1, TI2 and δt are respectively time to saturation, time to imaging and transit time as deﬁned by the QUIPSS II tagging scheme. The
relationship between PaO2 and arterial T1b is taken to be linear (as per Ma and colleagues, (Ma et al., 2014)) and described by:
T bPaO c= +b1, 2 (A-8)
The unknown parameters were ﬁxed to literature values, with b=−5×10−4 (extrapolated from Ma and colleagues, (Ma et al., 2014)) and c=1.78
(from Lu and colleagues, (Lu et al., 2004)). As regards the contribution of PetO2 and to PetCO2 to calculated CaO2 and ΔPaCO2 respectively, local
variation of the haemodynamic response (hr(t)) was allowed modelling each of them separately as gamma-variate functions:
hr t t e t e( ) = maxη η η η t t− − /i i i i max (A-9)
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with tmax (ﬁxed to 0.2 s) denoting the time of peak and ηi free parameter determining the rise and fall times of the response (with i =CO2, O2).
Finally CMRO2 is calculated as:
CMRO OEF CBF CaO= · ·2 2 (A-10)
Supplementary material
Supplementary data associated with this article can be found in the online version at doi:10.1016/j.neuroimage.2017.03.028.
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